Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors

This article has been corrected: During production, the 4th affiliation was mistakenly added to the name of the last author, Dr. Andrew S. Moore. The proper affiliation information is shown below.

Original article: Oncotarget. 2019; 10:5755–5767. 5755-5767. https://doi.org/10.18632/oncotarget.27206

Amanda M. Smith^1,4,*, Christine R.C. Zhang^1,4,*, Alexandre S. Cristino^1,6, John P. Grady^1,5, J. Lynn Fink¹ and Andrew S. Moore^1,2,3

¹The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia

²Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia

³Child Health Research Centre, The University of Queensland, South Brisbane, Australia

⁴Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America

⁵Current address: Garvan Institute of Medical Research, Darlinghurst, Australia

⁶Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia

^*These authors contributed equally to this work